Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone is a hydroxy-1,4-naphthoquinone analogue of ubiqu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Fiorillo, Marco, Lamb, Rebecca, Tanowitz, Herbert B., Mutti, Luciano, Krstic-Demonacos, Marija, Cappello, Anna Rita, Martinez-Outschoorn, Ubaldo E., Sotgia, Federica, Lisanti, Michael P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085139/
https://ncbi.nlm.nih.gov/pubmed/27136895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9122
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak